帕瑞昔布抑制乳腺癌改良根治术后中性粒细胞与淋巴细胞比值升高

发布时间：2018-01-30 09:28

本文关键词： 乳腺癌围手术期帕瑞昔布中性粒细胞与淋巴细胞比值　出处：《中南大学学报(医学版)》2017年09期 　论文类型：期刊论文

【摘要】：目的:通过观察环氧合酶(cyclooxygenase 2,COX-2)抑制药帕瑞昔布对乳腺癌改良根治术后患者外周血中性粒细胞与淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)的影响,探讨其抑制围手术期炎症反应的机制。方法:收集行乳腺癌改良根治术的患者入组,其中帕瑞昔布组20例,对照组20例。帕瑞昔布组患者于全麻诱导时、术后第1天和第2天各静脉注射帕瑞昔布40 mg(5 m L);对照组在相同的时间点静脉注射同等体积的生理盐水。两组患者分别于手术当天、术后第1天、术后第3天和术后第7天清晨抽取2 m L静脉血,立即送入实验室进行血常规检测。结果:与术前相比,对照组术后第1天和第3天的NLR均显著升高(P0.05),术后第7天恢复至术前水平(P0.05);帕瑞昔布组术后第1天的NLR显著升高(P0.01),术后第3天恢复至术前水平(P0.05)。组间比较显示:术后第1天帕瑞昔布组的NLR明显低于对照组(P0.05),其余时间点差异无统计学意义(P0.05)。结论:帕瑞昔布能通过抑制乳腺癌患者术后NLR升高发挥抗炎和免疫保护作用,有望改善乳腺癌患者的预后。
[Abstract]:Objective: to observe cyclooxygenase 2 (cyclooxygenase 2). The ratio of neutrophils to lymphocytes in peripheral blood of patients with breast cancer after modified radical mastectomy. Neutrophil-to-lymphocyte ratio. Methods: 20 patients with modified radical mastectomy of breast cancer were enrolled in the study, including 20 patients in the pareoxib group. The control group (n = 20) was treated with paroxib 40 mg(5 / L intravenously on the 1st and 2nd day after general anesthesia induction. In the control group, the same volume of saline was injected intravenously at the same time point. 2 mL venous blood was taken from the patients of the two groups on the day of operation, on the first day after operation, on the third day after operation and on the morning of day 7 after operation. Results: compared with pre-operation, the NLR of the control group on the 1st and 3rd day after operation was significantly higher than that of the control group (P 0.05). On the 7th day after operation, the patients recovered to the preoperative level (P 0.05). The NLR of paroxib group increased significantly on the first day after operation (P 0.01). On the 3rd day after operation, the level of P0.05 was recovered to the preoperative level. The results of comparison between the two groups showed that the NLR of the pareoxib group was significantly lower than that of the control group on the 1st day after operation (P 0.05). Conclusion: paroxib can play an anti-inflammatory and immuno-protective role by inhibiting the increase of NLR in breast cancer patients after operation, which may improve the prognosis of breast cancer patients.
【作者单位】：中南大学湘雅三医院麻醉科;中南大学湘雅三医院普外科;
【基金】：湖南省自然科学基金(2017JJ3429)~~
【分类号】：R614;R737.9
【正文快照】： Methods:A total of 40 breast cancer patients undergone the modified radical mastectomy wererandomly divided into a parecoxib group(n=20)and a control group(n=20).The parecoxib groupreceived intravenous parecoxib(40 mg,5 m L)during general anesthesia indu

【相似文献】